Featured Company News - ContraVir Announces Issuance of New US Patent for Expansion of Cyclophilin Inhibitor Program
Research Desk Line-up: Akebia Therapeutics Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 23, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Edison based ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) ("ContraVir"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=CTRV. The Company announced on August 21, 2017, the issuance of a new patent, US 9,714,271 by the United States Patent and Trademark Office (USPTO), covering a broad collection of cyclophilin inhibitors. ContraVir anticipates that CRV431, the Company's lead cyclophilin inhibitor for use as an antiviral which is being developed for the treatment of hepatitis B virus (HBV), will be used in conjunction with tenofovir exalidex (TXLTM), its lead drug currently in Phase-2 clinical trials. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Akebia Therapeutics, Inc. (NASDAQ: AKBA) for due-diligence and potential coverage as the Company announced on August 08, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Akebia Therapeutics when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CTRV; also brushing on AKBA. Go directly to your stock of interest and access today's free coverage at:
Issuance of New Patent helps ContraVir to Expand beyond HBV Core Program
Commenting on the issuance, James Sapirstein, Chief Executive Officer of ContraVir, stated that the Company is pleased to have received the issuance of this additional patent, as it provides broad coverage of many compounds within its library of cyclophilin inhibitors. This also positions ContraVir for opportunities to potentially treat other diseases. He added that having a patented portfolio of cyclophilin inhibitors allows the Company to access additional disease indications and potentially expand beyond its core program in HBV.
ContraVir Provided Insights into MOA of its HBV-Optimized CRV431
The news release states that on April 04, 2017, ContraVir provided new insights into the mechanism of action (MOA) of its hepatitis B virus (HBV)-optimized cyclophilin inhibitor CRV431. Studies showed that CRV431 potently blocks the interaction between hepatitis B surface antigen (HBsAg), a key HBV protein, and cyclophilin A, an important cellular protein. The findings further elucidated the MOA of CRV431, and supported the Company's strategy of providing a functional cure, where HBV remained suppressed following the completion of drug treatment.
About Cyclophilin Inhibitors
Cyclophilins constitute one of the three families of peptidyl prolyl isomerase enzymes. Different types of cyclophilins are ubiquitous and differ in their cellular localization, enzymatic properties, and their role in protein folding, and play a key role in many diverse diseases including infectious diseases, inflammation, cell death, muscular dystrophy, ischemia reperfusion, and oncogenesis. Cyclophilin inhibitors are being developed to treat neurodegenerative diseases.
CRV431 belongs to a known drug class of cyclophilin inhibitors derived from cyclosporine A, and was designed specifically to optimize potency and selectivity against HBV, a hepatitis B virus that affects the liver and occurs in both acute and chronic modalities. CRV431 shows potential in experimental models to complement current hepatitis B treatments by reducing multiple markers of infection including HBV DNA, HBsAg, HBx, HBeAg, and HBV uptake by cells.
About ContraVir Pharmaceuticals, Inc.
Founded in 2013, ContraVir is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, specifically for the treatment of HBV infections. The Company is developing two novel anti-HBV compounds with complementary mechanisms of action. TXL™ currently in Phase-2a, is designed to deliver high intrahepatic concentrations of TFV, while minimizing off-target effects caused by high levels of circulating TFV. CRV431, the other anti-HBV compound, is a next-generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV.
Last Close Stock Review
At the close of trading session on Tuesday, August 22, 2017, ContraVir Pharma's stock price declined 6.16% to end the day at $0.54. A total volume of 886.22 thousand shares were exchanged during the session, which was above the 3-month average volume of 513.86 thousand shares. At Tuesday's closing price, the stock's net capitalization stands at $39.86 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.